Why the study?
Does dual antiplatelet therapy involving ticagrelor increase the risk of MACEs and recurrence in patients with spontaneous coronary artery dissection?
Does dual antiplatelet therapy involving ticagrelor increase the risk of MACEs and recurrence in patients with spontaneous coronary artery dissection?
Answers are grounded in this paper and cite their sources.
In patients with spontaneous coronary artery dissection, dual antiplatelet therapy involving ticagrelor is associated with an increased risk of MACE and recurrence, suggesting potent P2Y12 inhibitors may be harmful in this population.
This commentary refers to ‘The Australian–New Zealand spontaneous coronary artery dissection cohort study: predictors of major adverse cardiovascular events and recurrence’, by Q. Dang et al., https://doi.org/10.1093/eurheartj/ehaf097 and the discussion piece ‘Rethinking potent antiplatelet therapy in spontaneous coronary artery dissection before it harms’, by Q.M. Dang et al., https://doi.org/10.1093/eurheartj/ehaf1054. We read with interest the article by Dang et al.1 reporting the findings of the Australian–New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) registry, which represents an important contribution to the understanding of this challenging clinical condition. We congratulate the authors for their rigorous methodology and the robust insights derived from this large multicentre cohort. Authors demonstrate that dual antiplatelet therapy (DAPT) involving ticagrelor was independently associated with an increased risk of major adverse cardiovascular events (MACEs) [adjusted hazard ratio (aHR), 1.8; 95% confidence interval (CI), 1.04–3.2; P = .037] and SCAD recurrence (aHR, 2.6; 95% CI, 2.1–5.3; P = .01), whereas DAPT with clopidogrel did not show such an association. These results are consistent with the findings of the European DISCO registry previously published in this journal by our group,2 which similarly reported a potentially harmful association between DAPT and outcomes in SCAD patients, particularly when more potent P2Y12 inhibitors were used. As a matter of fact, unpublished data from the whole DISCO registry cohort (regardless of interventional or conservative management) suggest a potential harmful role of ticagrelor towards MACE (aHR, 2.2; 95% CI, 1.2–3.9; P = .01), even if considering only patients undergoing percutaneous revascularization (n = 129),3 albeit not significant (18.0% vs 12.9%; P = .22).
No takes yet. Share an insight, caveat, or question.
Cerrato et al. (2025) conducted a letter in Spontaneous coronary artery dissection (SCAD). Dual antiplatelet therapy (DAPT) involving ticagrelor vs. DAPT with clopidogrel or other management was evaluated on Major adverse cardiovascular events (MACEs) (aHR 1.8, 95% CI 1.04-3.2, p=.037).
Synapse has enriched 10 related papers. Consider them for comparative context: